NEWSpublisher 2007 :: AngloChinese Investments
SEARCH COMPANY
name:
trunover in millions USD:
from:    to: 
R & D turnover in millions USD:
from:     to: 
NET profit:
from:    to: 
employees:
from:    to: 
COMPANIES
APPROVALS
ACTIVITIES ENGAGED IN
R & D
CLINICAL TRIALS
NON CLINICAL & PRECLINICAL
CHEMISTRY-CONTRACT MANUFACTURE
TEST
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY DETAILS » Covance back to previous page show list

Covance

address: 210Carnegie Center
Princeton
New Jersey
08540-6233
USA
contact: www.covance.com
Tel: 001 609 452 4440
Fax: 001 609 452 9375
key person: Chmn & CEO Joe Herring
John watson
Donald Kraft
James Lovatt
Irwin Lerner
J Randall MacDonald

trunover in millions USD: 1340
R & D turnover in millions USD: 0
NET profit: 142
year of financial results: 2006
employees: 8100

active in China: YES
partner in China: Covance
Shanghai
& Beijing

SFDA approved: YES
SFDA approved date: 09/05/2007

Approvals:
GLP: NO
GMP: YES
AAALAC: NO
SEPA: NO

Activities engaged in:
Manufacture: NO
Active Pharmaceutical: YES
R&D: YES
Ingredients: NO
Western Generics: NO
TCM: NO

R & D:
Discovery: NO
Work Up (pilot to production): YES
Analysis: YES
Quality Control: YES
Stability: YES
Batch Release: YES

Clinical trials:
Run/Manage: YES
Data management: YES
Support Labs: NO

Non clinical & preclinical:
Animal Testing: GLP: YES
New materials Safety Assessment: YES
Pharmaceuticals: YES
Agrochemicals: NO
Industrial & Other Chemicals: NO
Non GLP - Discovery ADME: NO

Chemistry-contract manufacture:
Generics: NO
API: NO
Licensed Drugs: NO

test:
R&D: YES
 

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.3 billion, global operations in more than 20 countries, and more than 8,100 employees worldwide. Offering drug development solutions from preclinical through commercialization, Covance is a world-class provider of the following service lines:

Research products

Antibody products and services

Nonclinical development services

Risk management services

Clinical pharmacology services

Central laboratory/Covance local laboratory services

Cardiac safety services

Clinical development services

Commercialization services

Covance — Meeting Your Needs

Proving early safety

Conducting first in human studies

Conducting proof of concept studies

Proving clinical safety and efficacy

Filing for marketing approval

Launching and marketing a drug

Ensuring patient safety and access

Managing risk

Managing over 15,000 clinical trial protocols in 100 countries on 6 continents, Covance provides the experience and exceptional customer service to advance your compound along the drug development continuum. Strategic partnerships built on decades of success — Covance is dedicated to helping bring your miracles to market sooner



With a commitment to meeting your needs, Covance offers unparalleled expertise, experience and results. Covance knows the significant pressures pharmaceutical and biotechnology companies of all sizes face in developing and launching drugs backed by strong data.

With a business built around your needs, our streamlined approach to drug development means high quality, error-free data designed to help bring your drug to market as quickly, safely and cost effectively as possible, including:


AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.